Salem Radio Network News Tuesday, November 17, 2026

Health

Boehringer, Zealand’s obesity drug did not raise heart risks in trial, data shows

Carbonatix Pre-Player Loader

Audio By Carbonatix

Nov 9 (Reuters) – Zealand Pharma and Boehringer Ingelheim’s experimental obesity drug did not increase the risk of serious heart problems compared to a placebo in a late-stage trial, the companies said on Monday.

• The study enrolled 5,530 adults with obesity who had cardiovascular diseases, chronic kidney diseases, or at least two weight-related complications or cardiovascular risk factors

• The trial met its main goal by showing that the drug, survodutide, did not increase the risk of major cardiovascular events, including heart attack, stroke and cardiovascular death

• Patients receiving survodutide lost up to 13.7% of their body weight after 72 weeks and also saw greater reductions in blood pressure and waist circumference than those on placebo, the companies said

• Stomach-related side effects were the most common, including nausea, vomiting, and diarrhea. About 20% of the patients on survodutide stopped treatment because of these side effects, compared with 1.9% on placebo

• Survodutide, a dual glucagon/GLP-1 receptor agonist licensed by Boehringer Ingelheim from Zealand Pharma, is being developed for obesity and related cardiometabolic diseases

• Boehringer, which holds global development and commercialization rights for survodutide, plans to submit an application for global regulatory approval to treat obesity

(Reporting by Kamal Choudhury in Bengaluru; Editing by Shinjini Ganguli)

Previous
Next
The Media Line News
X CLOSE